Remove 2021 Remove Communication Remove Labelling
article thumbnail

FDA-Approved Labeling: Is Enough Enough?

The FDA Law Blog

Livornese — I saw the sign…and the answer is no—FDA-approved labeling apparently is not enough under state failure-to-warn laws, according to certain courts.

article thumbnail

COVID At-Home Antigen Tests: If at First You Don’t Succeed Try, Try and Try Again

The FDA Law Blog

Ironically, a recent FDA safety communication points to a potential way out of this dilemma. In this safety communication, FDA advises the public as follows: If you test negative and have COVID-19 symptoms , you test again 48 hours later for a total of two tests.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Prescribing shift for Pfizer’s Paxlovid expands access but draws questions

Pharmaceutical Technology

Ganio says that, ideally, once an individual receives a positive Covid-19 result, they should call their pharmacy or communicate through a drive-through facility to minimize the risk of exposure. billion in global sales after its launch in late 2021 in the US and other countries, as per the company’s Q1 results. How to get Paxlovid.

Labelling 111
article thumbnail

OPDP Comes out Swinging With A Warning Letter on Unsubstantiated Efficacy

The FDA Law Blog

Prior to the CytoDyn letter in 2022, OPDP issued a Warning Letter in 2021 to CooperSurgical for a DTC video entitled “Paragard: Family Planning During the Pandemic” which failed to communicate ANY risk information. This seems to suggest that FDA expects this type of outcome claim to be included in labeling.

FDA 52
article thumbnail

Disrupted medical conferences: Lessons learnt

pharmaphorum

Towards the conclusion of 2021 many societies announced another shift in format; 2022 conferences would be hybrid, or increasingly and more realistically described as ‘physical with virtual participation options,’ or similar. This article summarises the most important lessons learnt during 2020 – 2021. Lessons learnt 2020-2021.

Labelling 105
article thumbnail

Sustainable pharma packaging: breaking down the barriers to adoption

European Pharmaceutical Review

And beyond the physical limitations, those instigating industry-wide change also face pushback in the boardroom, with a recent study citing poor communication between stakeholders and rigid practices among the key barriers to more circular product packaging. Consultancy.uk; 2021 [cited 2022Sep]. 2021 [cited 2022Sep]. References.

article thumbnail

Eliquis interactions to avoid

The Checkup by Singlecare

Hence, it is important to communicate openly with your healthcare providers about all medications, vitamins, and supplements you take to ensure proper medical advice and monitoring. Eliquis and grapefruit Grapefruit and grapefruit juice interact with the effectiveness of many medicines due to binding to the enzyme CYP3A4.